A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

Exclusion Criteria

• •1. Presence of the following ocular conditions in the study eye:
• •1. Any active ocular disease or condition that impact the subject to participate in the study or be a contraindication of IVT injections
• •2. Any intraocular surgery
• •3. Aphakia or complete absence of the posterior capsule
• •4. Prior corneal transplant
• •5. Scar or fibrosis greater than or equal to (\>=) 50% of CNV lesion or involving center of fovea
• •2. Presence of any of the following ocular conditions in either eye:
• •1. History of herpetic infection, idiopathic polypoidal choroidal vasculopathy (PCV), pathologic myopia, central serous chorioretinopathy (CSCR), adult onset foveal pattern dystrophy
• •2. Concurrent disease that could require medical or surgical intervention during the study period
• •3. Active/suspected ocular/periocular infection or active intraocular inflammation
• •4. History of idiopathic or autoimmune-associated uveitis
• •3. Any prior or ongoing medical condition or clinically significant screening laboratory value that may present a safety risk, interfere with study compliance, interfere with consistent study follow-up, or confound data interpretation throughout the longitudinal follow-up period
• •4. Has experienced a cardiovascular or cerebrovascular event within 12 months of informed consent
• •5. Females must not be pregnant or lactating
• •6. Current use of medications known to be toxic to the lens, retina or optic nerve
• •7. Use of any investigational new drug or other experimental treatment in the last 6 months prior to Day 1, and/or receipt of any prior gene therapy or ocular device implantation